Transaction Highlights Retirement of US$18.34 million of outstanding debt held by UEC (and previously U1A), resulting in Anfield now being debt free and UEC becoming the largest shareholder (~16% undiluted ownership). The transactions include a swap of UEC’s Slick...
Provisional patent filed (April 14, 2022) to support use of PD-001 plus cabazitaxel for primary, metastatic and chemotherapy-resistant prostate cancer Final study results show that oral cepharanthine (PD-001) plus cabazitaxel combination therapy significantly reduced...
TORONTO, April 11, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to...
Prototype medical device engineered to deliver sustained, sub-psychedelic quantities of candidate DMT-analogues In vitro, time dependent drug elution profile evaluated for three candidate molecules Biocompatibility of drug-loaded medical device demonstrates cell-based...
VANCOUVER, British Columbia, April 06, 2022 – Anfield Energy Inc. (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) (“Anfield” or “the Company”) is pleased to announce that it has engaged BRS Inc. and Wright Environmental Services to restart the permit application...
Committed to the ‘pipeline-in-a-pill’ approach with PD-001 for certain cancers and COVID-19 Advances cGMP manufacturing of clinical drug supply with Southwest Research Institute Receives final positive data for recently conducted prostate cancer model and...
